

**To:** Office of Attorney General  
[AGO.highcostprescriptiondrugs@vermont.gov](mailto:AGO.highcostprescriptiondrugs@vermont.gov)

**From:** Mylan Pharmaceuticals Inc.  
781 Chestnut Ridge Road  
Morgantown, West Virginia 26505

**Date:** December 18, 2018

**Re:** 18 V.S.A § 4637

---

In compliance with 18 V.S.A. § 4637, Mylan Pharmaceuticals Inc. hereby provides written notice that on December 15, 2018 it introduced the following new prescription drug to market:

- Mesalamine Suppository, 1000mg